Compare AstraZeneca plc (AZN) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Cincinnati Financial Corporation — how do they compare? AstraZeneca plc trades at $158.68 (market cap $248.14B), while Cincinnati Financial Corporation trades at $173.47 (market cap $26.58B). The key difference: AstraZeneca plc is far larger — about 9.3× Cincinnati Financial Corporation's market cap, and Cincinnati Financial Corporation pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| AZN | CINF | |
|---|---|---|
Market Cap | $248.14B | $26.58B |
Sector | Health | Financials |
52-Week High | $209.48 | $192.03 |
52-Week Low | $147.06 | $149.79 |
Enterprise Value | $275.41B | $25.71B |
Dividend Yield | 2.01% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Cincinnati Financial (CINF) trades at $173.86, down 1.7% on the day, with a bearish technical signal and key support at $172. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and a consistent dividend history, with a recent H1-26 dividend of $0.94 declared.
The outlook is cautiously optimistic, supported by a consensus price target of $195 and a 'Moderate Buy' analyst rating. Risks include catastrophe losses impacting underwriting and competitive pressures in commercial lines. Positive cash flow trends and rising investment income provide a solid foundation for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
